Camilo Colaco

ImmunoBiology

Prior to founding ImmBio, Dr Colaço was Director of Intellectual Property (IP) for the biotechnology company Quadrant Healthcare plc, where he was responsible for development of the IP portfolio that formed the basis of its successful listing on the London Stock Exchange and acquisition by Elan. Dr Colaço was responsible for generating the IP that formed their biomolecule stabilisation and delivery technology. In addition to his industry experience, Dr Colaço has worked in a number of leading instituations, including the University of Cambridge Medical School. He has a degree in Biochemistry from the University of London and PhD from the National Institute of Medical Research, London.

dont miss

The immunobiology of immunotherapy

Cancer Immunotherapy is a paradigm shift in cancer treatment which is now being recognised as a potentially curative treatment. Dr Colaco will summarise current approaches and present the approach to effective personalised cell-based cancer immunotherapy being initiated in Cambridge.

EVEN MORE SEMINARS

  • Prof Samuel Janes: Speaking at the Oncology Convention

    Prof Samuel Janes
    University College London Hospitals

    Coming soon

  • Mylaine Riobe MD, FABOIM, FACOG: Speaking at the Oncology Convention

    Mylaine Riobe MD, FABOIM, FACOG
    Riobe Institute of Integrative Medicine

    Cancer is not random! Evolving mechanisms for cancer causation and prevention

  • Rob Duncombe: Speaking at the Oncology Convention

    Rob Duncombe
    The Christie NHS Foundation Trust

    Medicine Optimisation in Oncology. How to achieve best value.

  • Cheng Boon: Speaking at the Oncology Convention

    Cheng Boon
    Worcestershire Royal Hospital

    Consultant Clinical Oncologist, GI and Head & Neck

  • Chris Curtis: Speaking at the Oncology Convention

    Chris Curtis
    The Swallows Head & Neck Cancer Charity

    A patient’s journey ‘Cancer to the palace in 6yrs’